TheraRadar
Clinical-Stage Companies / RedHill Biopharma Limited

RedHill Biopharma Limited

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 2/16/2021

16
Total Trials
8
Phase 3
9
Phase 2
0
Recruiting
204
Score

Pipeline by Phase

Phase 3
8
Phase 2
9
Phase 1
4

Therapeutic Focus

COVID-19 Lung Infection Helicobacter Pylori Infection Dyspepsia Cholangiocarcinoma

Clinical Trials (16)

NCT04616924 Phase 3 TERMINATED

RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

Started: 12/1/2020

NCT03009396 Phase 3 COMPLETED

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

Started: 3/18/2017

NCT01951326 Phase 3 COMPLETED

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

Started: 9/1/2013

NCT03198507 Phase 3 COMPLETED

ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

Started: 6/18/2017

NCT01980095 Phase 3 COMPLETED

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

Started: 11/1/2013

NCT02246439 Phase 3 COMPLETED

BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

Started: 12/8/2014

NCT04467840 Phase 2 COMPLETED

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

Started: 8/21/2020

NCT03377179 Phase 2 COMPLETED

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

Started: 3/7/2018

NCT04723537 Phase 2 TERMINATED

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

Started: 2/16/2021

NCT04414618 Phase 2 COMPLETED

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Started: 7/2/2020

NCT02757105 Phase 2 COMPLETED

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Started: 5/19/2016

NCT01717664 Phase 2 COMPLETED

Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)

Started: 6/1/2013

NCT02757326 Phase 1 TERMINATED

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

Started: 12/13/2016

NCT04502069 Phase 1 WITHDRAWN

Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen

Started: 8/1/2020

NCT01488513 Phase 1 COMPLETED

ABC294640 in Treating Patients With Advanced Solid Tumors

Started: 8/1/2011

NCT02229981 Phase 1 WITHDRAWN

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Started: 7/1/2014

Drug Candidates

Opaganib ABC294640 Hydroxychloroquine Sulfate 200 MG RHB-204 Part A: Upamostat 200 mg Part A: Upamostat 400 mg Part B: Upamostat 200 or 400 mg RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) RHB-104 RHB-105
Activity Status: Stale
Last Trial Started: 2/16/2021
Last Trial Ended: 8/28/2023
Trials (12 months): 0
Completed Trials: 11
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.